Primary deep cutaneous candidiasis caused by Candida duobushaemulonii in a 68-year-old man: the first case report and literature review

Mycoses

Volumn 59, Issue 12, 2016, Pages 818-821

  Fang, Szu Yun ^a   Wei, Kai Che ^a   Chen, Wen Chieh ^b,c   Lee, Shin Jung ^a,d   Yang, Kuo Chung ^a   Wu, Chieh Shan ^a   Sun, Pei Lun ^e,f  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Immunologie Zentrum Zurich   (Switzerland)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^f CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Candida duobushaemulonii; Candida haemulonii complex; candidiasis; cutaneous; deep

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; DNA 26S; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; RIBOSOME DNA; VORICONAZOLE; ANTIFUNGAL AGENT; FUNGAL DNA;

ACUTE KIDNEY FAILURE; AGED; ANTIFUNGAL SUSCEPTIBILITY; ANTIFUNGAL THERAPY; ARTICLE; CANDIDA; CANDIDA DUOBUSHAEMULONII; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FAT NECROSIS; FOLLOW UP; FUNGAL STRAIN; FUNGUS ISOLATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MACROPHAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPHIL CHEMOTAXIS; NUCLEOTIDE SEQUENCE; PERIODIC ACID SCHIFF STAIN; PRIORITY JOURNAL; SKIN BIOPSY; SKIN CANDIDIASIS; SKIN NECROSIS; SKIN ULCER; ULCER HEALING; CLASSIFICATION; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; PHYSIOLOGY;

AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, CUTANEOUS; DNA, FUNGAL; HUMANS; MALE;

EID: 84986266760     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12540     Document Type: Article

References (32)

1. van Uden, Kolipinski MC. Torulopsis haemulonii nov. spec., a yeast from the Atlantic Ocean. Antonie Van Leeuwenhoek. 1962;28:78–80.
2. Rodero L, Cuenca-Estrella M, Cordoba S, et al. Transient fungemia caused by an amphotericin B-resistant isolate of Candida haemulonii. J Clin Microbiol. 2002;40:2266–2269.
3. Giusiano G, Mangiaterra M, Garcia Saito V, Rojas F, Gomez V, Diaz MC. Fluconazole and itraconazole resistance of yeasts isolated from the bloodstream and catheters of hospitalized pediatric patients. Chemotherapy. 2006;52:254–259.
4. Kim MN, Shin JH, Sung H, et al. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infect Dis. 2009;48:e57–e61.
5. Ruan SY, Kuo YW, Huang CT, Hsiue HC, Hsueh PR. Infections due to Candida haemulonii: species identification, antifungal susceptibility and outcomes. Int J Antimicrob Agents. 2010;35:85–88.
6. Kim S, Ko KS, Moon SY, Lee MS, Lee MY, Son JS. Catheter-related candidemia caused by Candida haemulonii in a patient in long-term hospital care. J Korean Med Sci. 2011;26:297–300.
7. Khan ZU, Al-Sweih NA, Ahmad S, et al. Outbreak of fungemia among neonates caused by Candida haemulonii resistant to amphotericin B, itraconazole, and fluconazole. J Clin Microbiol. 2007;45:2025–2027.
8. Crouzet J, Sotto A, Picard E, Lachaud L, Bourgeois N. A case of Candida haemulonii osteitis: clinical features, biochemical characteristics, and antifungal resistance profile. Clin Microbiol Infect. 2011;17:1068–1070.
9. Gargeya IB, Pruitt WR, Meyer SA, Ahearn DG. Candida haemulonii from clinical specimens in the USA. J Med Vet Mycol. 1991;29:335–338.
10. Cendejas-Bueno E, Kolecka A, Alastruey-Izquierdo A, et al. Reclassification of the Candida haemulonii complex as Candida haemulonii (C. haemulonii group I), C. duobushaemulonii sp. nov. (C. haemulonii group II), and C. haemulonii var. vulnera var. nov.: three multiresistant human pathogenic yeasts. J Clin Microbiol. 2012;50:3641–3651.
11. Kim MS, Lee SM, Sung HS, et al. Clinical analysis of deep cutaneous mycoses: a 12-year experience at a single institution. Mycoses. 2012;55:501–506.
12. Milner JD, Brenchley JM, Laurence A, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 2008;452:773–776.
13. Lanternier F, Cypowyj S, Picard C, et al. Primary immunodeficiencies underlying fungal infections. Curr Opin Pediatr. 2013;25:736–747.
14. Lanternier F, Pathan S, Vincent QB, et al. Deep dermatophytosis and inherited CARD9 deficiency. N Engl J Med. 2013;369:1704–1714.
15. Rouzaud C, Hay R, Chosidow O, et al. Severe dermatophytosis and acquired or innate immunodeficiency: a review. J Fungi. 2015;2:4.
16. Puel A, Cypowyj S, Marodi L, Abel L, Picard C, Casanova JL. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol. 2012;12:616–622.
17. Ferwerda B, Ferwerda G, Plantinga TS, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med. 2009;361:1760–1767.
18. Bae GY, Lee HW, Chang SE, et al. Clinicopathologic review of 19 patients with systemic candidiasis with skin lesions. Int J Dermatol. 2005;44:550–555.
19. Xi L, Li X, Zhang J, Lu C, Xie T, Yin R. Good response in a patient with deep-seated subcutaneous ulcer due to Candida species. Mycopathologia. 2007;164:77–80.
20. Patterson JW, Brown PC, Broecker AH. Infection-induced panniculitis. J Cutan Pathol. 1989;16:183–193.
21. Schram AM, Kim B, Carlos C, Tetzlaff MT, Schuster M, Rosenbach M. Primary cutaneous Candida tropicalis infection in a patient with B-cell lymphoma. Cutis. 2014;93:204–206.
22. Bouza E, Munoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents. 2008;32(Suppl 2):S87–S91.
23. Chow JK, Golan Y, Ruthazer R, et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis. 2008;46:1206–1213.
24. Shoham S, Marwaha S. Invasive fungal infections in the ICU. J Intensive Care Med. 2010;25:78–92.
25. Pfaller MA, Woosley LN, Messer SA, Jones RN, Castanheira M. Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme. Mycopathologia. 2012;174:259–271.
26. Oh BJ, Shin JH, Kim MN, et al. Biofilm formation and genotyping of Candida haemulonii, Candida pseudohaemulonii, and a proposed new species (Candida auris) isolates from Korea. Med Mycol. 2011;49:98–102.
27. Sugita T, Takashima M, Poonwan N, Mekha N. Candida pseudohaemulonii sp. nov., an amphotericin B-and azole-resistant yeast species, isolated from the blood of a patient from Thailand. Microbiol Immunol. 2006;50:469–473.
28. Chatterjee S, Alampalli SV, Nageshan RK, Chettiar ST, Joshi S, Tatu US. Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris. BMC Genom. 2015;16:686.
29. Kathuria S, Singh PK, Sharma C, et al. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and Its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. J Clin Microbiol. 2015;53:1823–1830.
30. Ramos LS, Figueiredo-Carvalho MH, Barbedo LS, et al. Candida haemulonii complex: species identification and antifungal susceptibility profiles of clinical isolates from Brazil. J Antimicrob Chemother. 2015;70:111–115.
31. Muro MD, Motta Fde A, Burger M, Melo AS, Dalla-Costa LM. Echinocandin resistance in two Candida haemulonii isolates from pediatric patients. J Clin Microbiol. 2012;50:3783–3785.
32. Gabardi S, Kubiak DW, Chandraker AK, Tullius SG. Invasive fungal infections and antifungal therapies in solid organ transplant recipients. Transpl Int. 2007;20:993–1015.